Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at an accelerated rate. In MS, it has been shown that there is a reduction in synaptic density, which presents a potential target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

February 10, 2019
Open Access

Fibrinogen Induces Microglia-Mediated Spine Elimination and Cognitive Impairment in an Alzheimer's Disease Model

Neuron
Mario MerliniKaterina Akassoglou
September 4, 2019
Preprint
Open Access

Localized calcium accumulations prime synapses for phagocyte removal in cortical neuroinflammation

BioRxiv : the Preprint Server for Biology
Mehrnoosh JafariMartin Kerschensteiner
June 5, 2019
Review
Open Access

Synaptic Elimination in Neurological Disorders

Current Neuropharmacology
Pablo L CardozoFabíola M Ribeiro
June 28, 2016
Review
Open Access

Glutamate signalling: A multifaceted modulator of oligodendrocyte lineage cells in health and disease

Neuropharmacology
Sonia SpitzerRagnhildur T Káradóttir
August 24, 2018
Review
Open Access

Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions

Frontiers in Aging Neuroscience
Alessandra MusellaGeorgia Mandolesi
November 23, 2016
Review
Open Access

The role of Gpi-anchored axonal glycoproteins in neural development and neurological disorders

Molecular and Cellular Neurosciences
Gianfranco GennariniAndrew J W Furley
February 9, 2020
Review
Open Access

Curcumin's Nanomedicine Formulations for Therapeutic Application in Neurological Diseases

Journal of Clinical Medicine
Bahare SalehiJavad Sharifi-Rad
August 5, 2019
Review

The role of zinc, copper, manganese and iron in neurodegenerative diseases

Neurotoxicology
Leda MezzarobaEdna Maria Vissoci Reiche
August 20, 2020
Open Access

Fractalkine-Dependent Microglial Pruning of Viable Oligodendrocyte Progenitor Cells Regulates Myelination

Cell Reports
Ashley D Nemes-BaranTara M DeSilva
July 2, 2020
Open Access

Synaptic Loss in Multiple Sclerosis Spinal Cord

Annals of Neurology
Natalia PetrovaKlaus Schmierer
June 11, 2019
Review
Open Access

A review for the neuroprotective effects of andrographolide in the central nervous system

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Jiashu LuChao Huang
January 30, 2018
Review
Open Access

Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders

Nature Reviews. Neurology
Melanie D SweeneyBerislav V Zlokovic
July 17, 2020

Synaptic and complement markers in extracellular vesicles in multiple sclerosis

Multiple Sclerosis : Clinical and Laboratory Research
Pavan BhargavaDimitrios Kapogiannis
January 18, 2020
Comment / Editorial
Open Access

That Wasn't a Complement-Too Much C3 in Demyelinating Disease

Immunity
Wendy Xin, Jonah R Chan

Sign up to follow this feed and discover related papers.

Related Feeds

ALS

Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) share a considerable proportion of characteristics including the same neuropathological substrate of abnormally phosphorylated TAR DNA binding protein (TDP-43). Here are the latest discoveries pertaining to ALS, FTD and TDP-43.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS - Stress Granules

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Acute Disseminated Encephalomyelitis

Acute disseminated encephalomyelitis (ADEM) is a rare inflammatory demyelinating disease of the central nervous system. Discover the latest research on acute disseminated encephalomyelitis here.

© 2020 Meta ULC. All rights reserved
/feed-previews/synapse-loss-as-therapeutic-target-in/371c8616-9261-4314-b041-1af69c1703ff